CJC-1295 isn't available on pharmacy shelves in Dale or anywhere else for that matter — this is a specialist compound available through a dedicated online market. What this means for Dale researchers is that geography is secondary to your ability to assess COA data — and those quality checks are available to every researcher. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety screening. The sections below cover what Dale researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
What Studies Say About CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Dale studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate CJC-1295 Vendors
Before looking at individual vendors, establish a quality benchmark — so you can recognise whether a vendor meets it. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger severe inflammatory responses even at minute levels. For Dale researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before scaling up your order is standard practice in the community. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so unusually low prices consistently indicate quality reductions.
Order CJC-1295 — ships to Dale
COA-verified · International tracking · Research grade
All use of CJC-1295 in Dale or anywhere is research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; do not freeze and thaw reconstituted CJC-1295 multiple times by dividing into single-dose aliquots before freezing. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger dangerous immune responses at trace quantities, and no cost saving makes omitting this acceptable. The research literature on CJC-1295 should be read critically before beginning any research — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
